Topic: featured
Tolebrutinib lowers risk of disability progression in secondary MS
MELBOURNE: Tolebrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor, a treatment that specifically targets immune… read more
NDIS-approved disability accommodation company shuts down
TOWNSVILLE: Investors fear they are missing tens of thousands of dollars and have accused a… read more
Two autism homes now under construction in regional community
PERTH: Construction has commenced in January 2025 on two new homes in Ellenbrook for people… read more
NDIS applicant suffers “slings and arrows of outrageous misfortune”
BRISBANE: An NDIS applicant has been rebuffed by an appeals tribunal and will not get… read more
